Hong Kong’s equity market is witnessing growing interest from overseas companies seeking public listings, as strong IPO momentum and improving investor sentiment encourage global firms to explore fundraising opportunities in the city, according to Reuters.
Around 10 companies from countries including Indonesia, South Korea and Singapore have already filed for listings in Hong Kong this year, while several others are evaluating potential debuts, according to a Reuters report which cited an executive from Hong Kong Exchanges and Clearing Ltd (HKEX).
The foreign listing candidates span sectors such as technology, consumer goods and financial services, reflecting a broader diversification in Hong Kong’s IPO pipeline. The mix includes first-time public offerings, concurrent dual listings and sequential dual listings.
Experts believe the trend signals a structural shift in Hong Kong’s capital markets as the exchange attracts companies beyond those with direct China exposure.
Hong Kong has traditionally been the preferred offshore fundraising destination for Chinese firms. According to LSEG data cited by Reuters, 110 Chinese and Hong Kong companies raised $36.4 billion through listings in 2025. While international listings remain a smaller portion of the overall market, the expected number of foreign IPOs this year could mark Hong Kong’s strongest year for overseas debuts since at least 2020.
The renewed interest comes as mainland Chinese and Hong Kong equity markets regain strength and foreign capital flows improve. Analysts say the improving market environment is helping Hong Kong reposition itself as a broader international fundraising hub.
Swiss-based agricultural and seeds company Syngenta Group is planning a listing in Hong Kong that could raise up to $10 billion later this year. Market participants believe such a high-profile deal could significantly strengthen HKEX’s appeal among multinational issuers.
Among the companies reportedly exploring potential Hong Kong listings are Singapore-based biotech firm Engine Biosciences and U.S.-based NiKang Therapeutics, according to Reuters sources familiar with the matter. Discussions remain preliminary and the plans could still change.
Malaysia’s logistics company Teleport also told Reuters that Hong Kong is one of the venues under consideration for a future public listing as part of its long-term expansion strategy.
LSEG data compiled earlier this month showed that as many as 12 foreign companies could be part of Hong Kong’s 2026 IPO pipeline. Potential candidates reportedly include U.S.-based blockchain infrastructure company Blockdaemon, Malaysian conglomerate Capital A, and British biopharmaceutical firm Allergy Therapeutics.
HKEX said seven international companies have already listed in Hong Kong in 2025. However, foreign listings still account for a relatively small share of the exchange’s overall activity. Since 2000, overseas firms have raised around $22 billion through 156 deals in Hong Kong, according to LSEG data.
Market experts say the current wave of foreign interest differs from the previous cycle seen roughly 15 years ago, which was dominated largely by luxury and consumer brands such as Prada and Samsonite. This time, the pipeline is more diverse across industries, geographies and listing formats.
Investment bankers and legal advisers believe Hong Kong’s investor base remains one of its biggest advantages.
Industry experts also pointed to rising Chinese demand for strategic minerals, growing investor appetite for artificial intelligence and biotech companies, and improving analyst coverage as factors boosting Hong Kong’s competitiveness against global exchanges such as Nasdaq.
As global firms increasingly look towards Asia for capital and expansion opportunities, analysts say Hong Kong’s role as an international fundraising centre could continue to strengthen in the coming years.
